7月核心荐股

Group 1: Company Performance - 和誉-B (2256.HK) has a total market value of HKD 70 billion, with a price increase of 137.1% since its inclusion on November 1, 2024[2] - 宜明昂科-B (1541.HK) has a market value of HKD 49 billion, showing a price drop of 73.7% since its inclusion on April 2, 2025[2] - 康哲药业 (0867.HK) has a market value of HKD 293 billion, with a price increase of 54.6% since its inclusion on November 1, 2024[2] Group 2: Financial Metrics - 和誉-B's PE ratio is projected to be 236.60 for 2024, decreasing to 48.67 by 2026[2] - 宜明昂科-B's EPS is expected to be -0.91 in 2024, improving to -0.60 in 2025[2] - 康哲药业's PE ratio is 16.65 for 2024, with a slight decrease in profit expected in 2025[2] Group 3: Strategic Developments - 和誉-B signed a licensing agreement with Merck worth USD 605.5 million, granting exclusive commercialization rights in Greater China[2] - 美兰空港 (0357.HK) is expected to improve operational efficiency through the management of three airports in Hainan Free Trade Port[2] - 阅文集团 (0772.HK) has seen its IP derivative business grow, with a GMV exceeding HKD 500 million in 2024[2] Group 4: Market Outlook - 连连数字 (2598.HK) is positioned to potentially obtain a stablecoin issuance license, indicating significant future growth potential[2] - 蒙牛乳业 (2319.HK) is expected to maintain a high dividend yield, supported by a favorable competitive landscape in the education sector[3]